February 2, 2017 / 10:31 PM / 9 months ago

BRIEF-IntelliPharmaCeutics announces FDA acceptance for filing of marketing application for Rexista

Feb 2 (Reuters) - IntelliPharmaCeutics International Inc

* IntelliPharmaCeutics announces FDA acceptance for filing of NDA for Rexista (oxycodone hydrochloride extended release), an abuse deterrent opioid analgesic for the treatment of moderate to severe pain

* IntelliPharmaCeutics International Inc - FDA set a target action date under prescription drug user fee act (“PDUFA”) of September 25, 2017

* IntelliPharmaCeutics International Inc - FDA has determined that company’s application is sufficiently complete to permit a substantive review Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below